BioMedNewsBreaks Archive - Page 17 of 250

FridaySep 12, 2025 9:25 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Expands IP Portfolio with New U.S. Patent Filings

HealthLynked (OTCQB: HLYK), a leader in patient-centric healthcare technology, announced the submission of two new U.S. patent applications covering a Universal Patient Identifier (UPIN) system designed to unify health records without relying on Social Security numbers and an AI Appointment Scheduling Agent capable of multilingual, personalized booking across providers, specialties, and insurance networks, further strengthening the company’s intellectual property portfolio and advancing its mission to secure medical data access, streamline care coordination, and enhance patient experience. To view the full press release, visit https://ibn.fm/cUoXt About HealthLynked Corp HealthLynked Corp. enhances healthcare through personalized care management that improves outcomes and reduces costs.…

ThursdaySep 11, 2025 9:20 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in MarketScreener Editorial on Targeted AI Applications

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for the more accurate screening, diagnosis and treatment of breast cancers, announced its sponsored placement in a MarketScreener.com editorial titled From Healthcare to Automation: Investing In Next AI Wave. The article discusses the growing adoption of specialized AI applications across industries and features Izotropic’s IzoView technology as a rare early-stage medtech opportunity with the potential to establish a new standard of care in breast cancer imaging. To view the full press release, visit https://ibn.fm/OOA6A About Izotropic: More information about Izotropic Corporation can be found on its corporate…

WednesdaySep 10, 2025 1:01 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted by revenue of $1.29 million, up 50.87% year over year, and cash reserves of $6.9 million. The company said the strong balance sheet supports the advancement of AVERSA(TM) Fentanyl, its lead product candidate, which has a Type C FDA meeting scheduled for Sept. 18. Nutriband emphasized that the NDA for AVERSA Fentanyl will rely on data from a single Phase 1 Human Abuse Potential study, with no Phase 2 or Phase 3 trials required. If approved, the patch could become the first and only abuse-deterrent…

WednesdaySep 10, 2025 12:23 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy and targeted treatments for cancer and underserved diseases, announced it has selected IBN to spearhead its corporate communications. Oncotelic is advancing therapies for difficult-to-treat and rare conditions, including pediatric cancers and aggressive solid tumors, with its lead candidate OT-101 currently in a Phase 3 trial for pancreatic ductal adenocarcinoma. Led by Chairman and CEO Dr. Vuong Trieu, co-inventor of Abraxane(R), the company is building a multi-asset pipeline supported by proprietary AI platform PDAOAI and a 45% stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited…

WednesdaySep 10, 2025 10:34 am

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary RADR(R) AI platform, is featured in the latest episode of IBN’s BioMedWire Podcast. President, CEO and Director Panna Sharma discusses the company’s mission to accelerate cancer drug development using AI, outlines progress across three ongoing clinical trials and shares his outlook on the future of precision neuro-oncology. To view the full press release, visit https://ibn.fm/ITg2o About Lantern Pharma Lantern Pharma is an AI company transforming the cost, time, and failure rate of oncology drug discovery and development. Lantern's proprietary AI platform RADR(R) uses machine learning…

TuesdaySep 09, 2025 2:54 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently released second quarter 2025 financial results and provided an update on clinical programs. “The company emphasized progress toward an NDA submission for its lead asset CNM-Au8® in ALS, expected in the fourth quarter of 2025,” reads an article discussing this. “We look forward to engaging with the FDA in our upcoming meeting this quarter focused on the extensive survival data that CNM-Au8® has generated in ALS patients,” said CEO Rob Etherington.…

TuesdaySep 09, 2025 11:43 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Signs Deal with Worldwide Leader in Specialized Diagnostics

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced a Research License and Exclusive Commercial Option Rights Agreement with Werfen’s Immunoassay Technology Center to assess antiphospholipid syndrome (“APS”) using Volition’s Nu.Q H3.1 Neutrophil Extracellular Traps (“NETs”) assay on Werfen platforms. “We are proud to have entered into this agreement with Werfen, as we implement our strategy to out license our proprietary Nu.Q NETs test to large worldwide companies to leverage their knowledge of specific diseases, product development, regulatory experience and their installed base of proprietary analyzers,” said Gael Forterre, Chief Commercial Officer at Volition. Marta Palicio, Werfen’s Immunoassay…

TuesdaySep 09, 2025 11:32 am

BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone

Gyre Therapeutics (NASDAQ: GYRE) has made strong progress through the first three quarters of FY2025, according to a report by Noble Capital Markets Senior Vice President and Equity Research Analyst Robert LeBoyer. The company posted continued sales growth from two recently launched products, submitted an application for Hydronidone approval in China, and initiated a U.S. Phase 2 trial for the drug. Gyre also named Dr. Han Ying, a board member since January 2025, as CEO. Phase 3 data for Hydronidone in chronic hepatitis B-associated fibrosis met its primary endpoint of fibrosis regression, supporting an NMPA filing in 3Q25. With Breakthrough…

MondaySep 08, 2025 11:41 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reports Study Showing Comparable Accuracy Between HeartBeam System and Standard 12-Lead ECG in Detecting Arrhythmias

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care with personalized insights, announced study results showing no significant differences in detecting atrial fibrillation, atrial flutter and sinus rhythm when its deep learning algorithms were applied to the HeartBeam System versus standard 12-lead ECGs. Data from 201 patients, presented at HRX Live 2025 in Atlanta by Dr. Joshua Lampert of Mount Sinai Heart, demonstrated high accuracy rates in both groups (94.5% HeartBeam vs. 95.5% standard 12-lead). CEO Rob Eno said the findings highlight the potential of HeartBeam’s compact, 3D device to expand advanced cardiac monitoring to settings where…

MondaySep 08, 2025 9:45 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE Therapeutics Inc. has closed the acquisition of Dura Medical, a revenue-generating and EBITDA-positive provider of interventional psychiatry services in Naples and Ft. Myers, Florida. Dura, founded in 2018, delivers treatments for depression, PTSD, suicidality, anxiety, and chronic pain through Ketamine Infusion Therapy, Transcranial Magnetic Stimulation, Spravato(R), Stellate Ganglion Blocks, and traditional psychiatry. The acquisition, along with pending deals for Neurospa TMS and Cohen and Associates, expands HOPE’s planned network to more than eight locations across Florida. Stephen Durand, Dura’s founder and a U.S. Army veteran,…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Expands IP Portfolio with New U.S. Patent Filings

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in MarketScreener Editorial on Targeted AI Applications

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Signs Deal with Worldwide Leader in Specialized Diagnostics

BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Reports Study Showing Comparable Accuracy Between HeartBeam System and Standard 12-Lead ECG in Detecting Arrhythmias

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search